Physician

Alexander Aizman, M.D.,

According to 2025 Medicare claims, Alexander Aizman, M.D., (NPI: 1659328011) practices ophthalmology in the Pittsburgh, PA market, with the plurality of this provider's patient population coming from Allegheny, PA. This provider's primary affiliated billing organization is RETINA VITREOUS CONSULTANTS INC. (NPI: 1063444123; TIN: 251492985) and primary practice location at 15146-2357. Aizman is affiliated with the Community Care of Brooklyn IPA, Inc. (ACO ID: A4723), participating under the MSSP model.

Aizman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 978 traditional Medicare patients, billed 16,114 HCPCS/CPT codes, and received $858,426 in Medicare payments. The top billing code was 92014 (Established patient complete exam of visual system). Part D data shows 969 prescription claims across 274 beneficiaries totaling $44,739 in drug costs, led by Combigan (Brimonidine Tartrate/Timolol). No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have fallen sharply in recent years, from $180,364 to $44,739. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$429K$858K2015 Medicare payment: $459,277 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $439,261 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $427,329 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $425,646 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $450,734 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $344,042 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $376,035 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $353,612 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $352,535 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $858,426 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20159304,821$459,277
20169775,035$439,261
20171,0844,942$427,329
20181,0634,911$425,646
20191,1015,146$450,734
20208603,847$344,042
20219044,300$376,035
20228494,227$353,612
20238584,201$352,535
202497816,114$858,426

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$90K$180K2015 Drug cost: $180,364 (USD; Tot_Drug_Cst)2016 Drug cost: $157,664 (USD; Tot_Drug_Cst)2017 Drug cost: $171,293 (USD; Tot_Drug_Cst)2018 Drug cost: $165,907 (USD; Tot_Drug_Cst)2019 Drug cost: $156,590 (USD; Tot_Drug_Cst)2020 Drug cost: $124,564 (USD; Tot_Drug_Cst)2021 Drug cost: $121,139 (USD; Tot_Drug_Cst)2022 Drug cost: $97,123 (USD; Tot_Drug_Cst)2023 Drug cost: $77,238 (USD; Tot_Drug_Cst)2024 Drug cost: $44,739 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20154232,416$180,364
20163802,326$157,664
20174732,685$171,293
20183752,325$165,907
20193632,078$156,590
20203081,745$124,564
20212981,721$121,139
20222581,365$97,123
20232511,066$77,238
2024274969$44,739

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
92014Established patient complete exam of visual system352419$110
67028Injection of drug into eye338549$100
92012Established patient problem focused exam of visual system176353$82
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more253333$73
92134Imaging of retina7791,176$35

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
CombiganBrimonidine Tartrate/Timolol14440$6,873
Prednisolone AcetatePrednisolone Acetate1445,871$6,657
LumiganBimatoprost18704$6,279
Brimonidine TartrateBrimonidine Tartrate503,119$5,437
LatanoprostLatanoprost30418,992$3,402

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

FAQ

What Medicare data is available for Alexander Aizman, M.D., ?

Tedicare shows public-source Medicare data for Alexander Aizman, M.D., (NPI 1659328011), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alexander Aizman, M.D., have ACO affiliation data?

Alexander Aizman, M.D., is shown with ACO affiliation data for Community Care of Brooklyn IPA, Inc. (MSSP, ACO ID A4723).

What billing organization is linked to Alexander Aizman, M.D., ?

Alexander Aizman, M.D., is linked to RETINA VITREOUS CONSULTANTS INC. (billing NPI 1063444123) in the available physician profile data.

Does Alexander Aizman, M.D., have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.